ClinicalTrials.gg
CompletedNCT03609775Updated Oct 15, 2018

A Study to Investigate the Drug-drug Interactions Between ACT-541468 and Ethanol in Healthy Subjects

A Phase 1 interventional study of ACT-541468 and ACT-541468 placebo in Healthy, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-15.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Oct 2018, 8 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

A study to investigate the drug-drug interactions between ACT-541468 and ethanol in healthy subjects

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.

Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed prior to any study-mandated procedure.
  • Healthy male and female subjects aged between 18 and 45 years (inclusive) at screening.
  • Women of must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 pre-dose of each treatment period. They must consistently and correctly use a reliable method of , be sexually inactive, or have a vasectomized partner.
  • Women of non-childbearing potential (i.e., ).
  • of 18.0 to 32.0 kg/m2 (inclusive) at screening.
  • Healthy on the basis of medical history, physical examination, cardiovascular assessments and serology and laboratory tests.
  • Previous experience with alcohol consumption and, therefore, familiar with the effects of alcohol.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
  • Excessive caffeine consumption, defined as ≥ 800 mg per day at screening.
  • Nicotine intake within 3 months prior to screening and inability to refrain from nicotine intake from screening until End-of-Study (EOS).
  • Previous treatment with any prescribed medications (including vaccines) or over-the-counter (OTC) medications (including herbal medicines such as St John's Wort, homeopathic preparations, vitamins, and minerals) within 2 weeks prior to first study treatment administration.
  • History or clinical evidence of alcoholism or drug abuse.
  • History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of more than 21 units or an average daily intake of more than 3 units (males), or defined as an average weekly intake of more than 14 units or an average daily intake of more than 2 units (females).
  • Individuals of Asian descent or other individuals reporting ethanol intolerance.
  • Modified Swiss Narcolepsy Scale total score \< 0 at screening or history of narcolepsy or cataplexy.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Treatment A (ethanol + ACT-541468)

    5 h i.v. ethanol clamp at a level of 0.6 g/L in combination with a single oral dose of ACT-541468 (50 mg)

    Drug: ACT-541468 · Other: Ethanol 10%

  • Experimental
    Treatment B (ethanol placebo + ACT-541468)

    5 h i.v. placebo clamp in combination with a single oral dose of ACT-541468 (50 mg)

    Drug: ACT-541468 · Other: Ethanol placebo

  • Experimental
    Treatment C (ethanol + ACT-541468 placebo)

    5 h i.v. ethanol clamp at a level of 0.6 g/L in combination with a single oral dose of matching ACT-541468 placebo

    Other: ACT-541468 placebo · Other: Ethanol 10%

  • Experimental
    Treatment D (ethanol placebo + ACT-541468 placebo)

    5 h i.v. placebo clamp in combination with a single oral dose of matching ACT-541468 placebo

    Other: ACT-541468 placebo · Other: Ethanol placebo

Interventions

  • One tablet of 50 mg ACT-541468 will be administered orally.

  • OtherACT-541468 placebo

    Matching ACT-541468 placebo will be administered orally as 1 tablet.

  • OtherEthanol 10%

    Ethanol 10% w/v solution in 5% glucose will be administered i.v. for 5 h and clamped at an ethanol level of 0.6 g/L.

  • OtherEthanol placebo

    Matching placebo for the ethanol infusion (i.e., 5% glucose solution) will be administered i.v. for 5 h.

06

What researchers measure

Primary outcomes

  1. Change from baseline for saccadic peak velocity (degrees/sec) to assess sedation

    Time frame: Several timepoints on Day 1; for up to 24 hours post-dose

Other outcomes

  1. Change from baseline for smooth pursuit (%) to assess eye movement coordination and attention

    Time frame: Several timepoints on Day 1; for up to 24 hours post-dose

  2. Change from baseline for adaptive tracking (%) to assess visuo-motor control and vigilance

    Time frame: Several timepoints on Day 1; for up to 24 hours post-dose

  3. Change from baseline for body sway (antero-posterior in mm / 2 min) to assess postural stability

    Time frame: Several timepoints on Day 1; for up to 24 hours post-dose

  4. Change from baseline for visual analog scales (VAS) Bond & Lader to assess subjective alertness, mood, and calmness

    Time frame: Several timepoints on Day 1; for up to 24 hours post-dose

  5. Change from baseline for VAS for alcohol intoxication to assess subjective effects of ethanol

    Time frame: Several timepoints on Day 1; for up to 24 hours post-dose

  6. ACT-541468 PK endpoints for treatments A and B: Area under the plasma concentration-time curve (AUC) from time zero to 24 h (AUC0-24)

    Time frame: Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose

  7. ACT-541468 PK endpoints for treatments A and B: AUC from zero to infinity (AUC0-∞)

    Time frame: Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose

  8. ACT-541468 PK endpoints for treatments A and B: Maximum plasma concentration (Cmax)

    Time frame: Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose

  9. ACT-541468 PK endpoints for treatments A and B: Time to reach Cmax (tmax)

    Time frame: Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose

  10. ACT-541468 PK endpoints for treatments A and B: Terminal elimination half-life (t½)

    Time frame: Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose

  11. Ethanol PK endpoints for treatments A and C: Breath ethanol concentrations (BrEC)

    Time frame: Several timepoints on Day 1; for up to 24 hours post-dose

  12. Ethanol PK endpoints for treatments A and C: Total ethanol dose (in grams) required to maintain the 0.6 g/L ethanol clamp

    Time frame: Several timepoints on Day 1; for up to 5 hours

  13. Safety endpoints: Treatment-emergent AEs from study treatment administration up to EOT in each treatment period

    Time frame: AEs from Day 1 to Day 2 (EOT/EOS); for up to 2 days post-dose

  14. Safety endpoints: Treatment-emergent SAEs from study treatment administration up to EOT in each treatment period

    Time frame: SAEs from Screening to Safety follow up; for up to 14 weeks

07

Study locations

1 site
  • Centre For Human Drug Research
    Leiden, 2333, Netherlands
08

References and documents

Publications

  • Berger B, Brooks S, Zuiker R, Richard M, Muehlan C, Dingemanse J. Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects. CNS Drugs. 2020 Dec;34(12):1253-1266. doi: 10.1007/s40263-020-00768-8. Epub 2020 Nov 18. PubMed 33205362 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Oct 2018, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2018
First posted
Aug 1, 2018
StartActual
Aug 28, 2018
Primary completionActual
Oct 9, 2018
CompletionActual
Oct 9, 2018
Last update
Oct 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03609775
Responsible party
Sponsor
First posted
Aug 1, 2018
Start date
Aug 28, 2018
Primary completion
Oct 9, 2018
Completion
Oct 9, 2018
Last update
Oct 15, 2018

Study contacts

Pascale Gasser
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daridorexant

Start the discussion